• IL-1β Drives ACE2 Upregulation and Macrophage SARS-CoV-2 Inf

  2026-06-23

  Lee et al. provide direct evidence that inflammatory signaling via IL-1β induces NF-κB-mediated ACE2 expression in lung macrophages, enabling productive SARS-CoV-2 infection. Their humanized ACE2 mouse model offers refined mechanistic insights and more clinically relevant inflammatory responses compared to legacy models, informing future COVID-19 pathogenesis studies.

• Pepstatin A: Applied Aspartic Protease Inhibitor Workflows

  2026-06-23

  Pepstatin A’s potency as an aspartic protease inhibitor enables high-fidelity research across viral protein processing and osteoclast differentiation models. This guide translates the latest protocol innovations and troubleshooting strategies into actionable steps for maximizing reproducibility in complex biomedical assays.

• Ivermectin: Broad-Spectrum Anti-Parasitic for Advanced Resea

  2026-06-22

  Ivermectin’s robust anti-parasitic profile and high assay reproducibility make it a mainstay in parasitology and drug development research. This article details advanced workflows, experimental troubleshooting, and translational insights—anchored by recent breakthroughs in tumor biology and stemness targeting.

• EdU Flow Cytometry Assay Kits (Cy5): Precision in Immunometa

  2026-06-22

  Explore how EdU Flow Cytometry Assay Kits (Cy5) empower precise cell proliferation measurement in immunometabolism and cancer research. Learn how this advanced click chemistry platform informs assay decisions and enables next-generation analysis distinct from standard protocols.

• Dinaciclib Synthetic Lethality in VHL-Deficient Renal Carcin

  2026-06-21

  The referenced study demonstrates that Dinaciclib, a cyclin-dependent kinase inhibitor, selectively induces death in clear cell renal cell carcinoma (CC-RCC) cells lacking the VHL tumor suppressor, exploiting a synthetic lethality mechanism. This finding highlights a promising therapeutic strategy for targeting CC-RCC with a defined genetic vulnerability, with implications for precision oncology.

• Optimizing WecA Purification: Advances in M. tuberculosis Me

  2026-06-20

  This study presents a robust methodology for the over-expression, purification, and kinetic characterization of Mycobacterium tuberculosis WecA, a challenging multi-transmembrane domain membrane protein and key anti-TB drug target. The work establishes a practical foundation for mechanistic studies and inhibitor discovery in membrane protein research.

• Amikacin (BAY416651): Dissecting Resistance in CREC Models

  2026-06-19

  Uncover the nuanced role of Amikacin (BAY416651) in dissecting resistance mechanisms among carbapenem-resistant Enterobacter cloacae. This article delivers advanced, evidence-based strategies for model system design, highlighting unique assay considerations and the latest molecular epidemiology.

• Death-Rate Genomic Screens Reveal Drug Mechanisms in Apoptos

  2026-06-19

  Honeywell et al. introduce MEDUSA, a simulation-assisted method that disentangles growth and death rates in pooled functional genomic screens, enabling precise identification of genetic determinants of drug-induced cell death. This advance clarifies how drugs like Bcl-2 inhibitors induce apoptosis versus non-apoptotic death, informing both mechanism-of-action studies and translational cancer research.

• TRIM21–ERK1/2 Axis in Pituitary Adenomas and the Role of Qui

  2026-06-18

  The reference study reveals how TRIM21 drives pituitary adenoma proliferation and drug resistance through ERK1/2 ubiquitination and phosphorylation. It further identifies Quisinostat as a promising epigenetic modulator capable of downregulating TRIM21, offering a novel strategy to counteract therapeutic resistance in these tumors.

• Vardenafil HCl Trihydrate: Selective PDE5 Inhibition in Rese

  2026-06-18

  Vardenafil HCl Trihydrate is a highly selective and potent PDE5 inhibitor, enabling precise dissection of cGMP signaling and smooth muscle relaxation mechanisms. Its molecular selectivity and solubility profile make it a benchmark tool for PDE5 inhibition assays and erectile dysfunction model systems. This article clarifies recent insights into proteoform-specific drug targeting and experimental design using Vardenafil.

• Rucaparib (AG-014699) Workflows for Radiosensitization Resea

  2026-06-17

  Rucaparib (AG-014699) enables precise, reproducible radiosensitization and DNA repair research—especially in cancer models with altered spliceosome regulation or DNA repair deficiencies. This guide translates the latest mechanistic discoveries into practical protocols, troubleshooting guidance, and advanced experimental strategies, leveraging APExBIO's trusted compound quality.

• WY-14643 (Pirinixic Acid): Strategic Insights for PPARα Rese

  2026-06-17

  This article delivers a translational roadmap for researchers leveraging WY-14643 (Pirinixic Acid) to dissect PPARα pathways in metabolic and inflammatory contexts. Integrating mechanistic omics data, real-world protocol guidance, and a competitive landscape analysis, it positions APExBIO’s WY-14643 as a benchmark tool for translational advances and discusses implications for future research into metabolic disorder modulation.

• Viral Degradation of RIPK3 Regulates Necroptosis and Inflamm

  2026-06-16

  Liu et al. uncover a viral mechanism in orthopoxviruses that promotes the ubiquitin-proteasome-mediated degradation of RIPK3, suppressing necroptosis and modulating inflammation during infection. This work highlights critical intersections between viral immune evasion, host cell death pathways, and the protein degradation machinery.

• Precision Protease Inhibition: Next-Gen Tools for Translatio

  2026-06-16

  This thought-leadership article explores the mechanistic necessity of broad-spectrum, EDTA-free protease inhibition for high-fidelity protein extraction in translational models—anchored by APExBIO’s Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO). Drawing from recent insights into macrophage-driven immunomodulation and advanced phosphorylation analysis, it provides strategic protocol guidance, workflow optimization, and a forward-looking perspective to empower researchers at the interface of discovery and clinical application.

• Rucaparib (AG-014699) in DNA Repair and Radiosensitization W

  2026-06-15

  Rucaparib (AG-014699) empowers researchers to dissect DNA repair pathways and optimize radiosensitization protocols, particularly in cancer models with altered spliceosome regulation. Its integration into experimental workflows offers unique leverage for both prostate and liver cancer research, especially as new findings highlight the impact of spliceosome acetylation on PARP inhibitor sensitivity.

16583 records 1/1106 page Next 12345 下5页 Last page